Last updated: September 8, 2026
CUROSURF, Chiesi Farmaceutici’s poractant alfa product, is an established neonatal respiratory-distress-syndrome therapy with durable hospital demand and limited conventional generic exposure. Its principal commercial risks are price pressure, competing animal-derived surfactants, hospital procurement, and potential development of alternative surfactant technologies rather than imminent patent expiry. Chiesi does not publicly disclose CUROSURF revenue separately, so the product’s financial trajectory must be inferred from company-level results, market structure, utilization, and regulatory barriers.
What is CUROSURF and how is it used?
CUROSURF is a natural pulmonary surfactant containing poractant alfa, a porcine-lung-derived preparation used to treat or prevent respiratory distress syndrome in premature infants. The U.S. Food and Drug Administration approved CUROSURF in 1999 under Biologics License Application No. 103909. The product is administered intratracheally through an endotracheal tube or approved minimally invasive surfactant-administration technique where clinically appropriate (FDA, 2023).
| Attribute |
CUROSURF profile |
| Active ingredient |
Poractant alfa |
| Product type |
Natural pulmonary surfactant |
| Source |
Porcine lung extract |
| Primary indication |
Respiratory distress syndrome in premature infants |
| U.S. approval |
1999 |
| U.S. sponsor |
Chiesi USA, Inc. |
| Reference product pathway |
Biologics License Application |
| Typical initial dose |
2.5 mL/kg, equivalent to 200 mg phospholipids/kg |
| Repeat dosing |
Up to two additional 1.25 mL/kg doses |
| Main care setting |
Neonatal intensive-care units |
| Key competitors |
Survanta and Infasurf in the United States |
CUROSURF’s initial 2.5 mL/kg dose is higher in volume than some competing products, but its high phospholipid concentration allows delivery of 200 mg/kg in the initial treatment. Clinical purchasing decisions depend on gestational age, neonatal protocols, clinician familiarity, dosing logistics, inventory, and price.
What is the market size and growth outlook for CUROSURF?
The addressable market is determined by premature births, the incidence of neonatal respiratory distress syndrome, access to neonatal intensive-care units, and the rate at which hospitals administer exogenous surfactant.
The World Health Organization estimates that approximately 13.4 million babies were born preterm in 2020, or more than one in 10 live births worldwide (World Health Organization, 2023). The number of infants who receive surfactant is materially lower because treatment depends on gestational age, respiratory status, local clinical practice, and availability of mechanical ventilation or noninvasive respiratory support.
Market growth is likely to be modest in mature markets:
- Premature-birth volumes create a recurring clinical base.
- Improved antenatal corticosteroid use and noninvasive respiratory support can reduce the number of infants requiring surfactant.
- Expanded neonatal-care capacity in emerging markets can increase adoption.
- Hospital procurement programs constrain unit pricing.
- CUROSURF benefits from clinical familiarity and established neonatal protocols.
The commercial market is therefore closer to a stable specialty hospital market than to a high-growth pharmaceutical category. Volume growth can arise in lower-access regions, while developed markets are more likely to generate price and share competition.
How has CUROSURF affected Chiesi’s financial trajectory?
Chiesi’s public financial disclosures provide group revenue, not a separate CUROSURF income statement. The company reported consolidated revenue of approximately €3.0 billion in 2023, compared with approximately €2.75 billion in 2022 (Chiesi Farmaceutici, 2024). Those figures include respiratory, rare-disease, specialty-care, and other products. They do not establish CUROSURF sales, growth, gross margin, or regional profitability independently.
| Financial question |
Publicly supportable conclusion |
| Is CUROSURF revenue separately disclosed? |
No, not in the cited Chiesi group reporting |
| Is the product commercially mature? |
Yes; U.S. approval dates to 1999 |
| Does CUROSURF contribute recurring revenue? |
Yes, through repeat hospital use in neonatal intensive care |
| Is product-level growth publicly quantifiable? |
No |
| Is CUROSURF strategically relevant? |
Yes, as an established specialty-care product with global distribution |
| Is the product likely a primary group growth driver? |
It is more likely a durable cash-flow contributor than the main source of corporate growth |
CUROSURF’s financial value is supported by several characteristics:
- Neonatal surfactant is administered in acute-care settings where treatment is protocol-driven.
- The product is used for a defined medical emergency rather than elective treatment.
- Clinical familiarity reduces switching friction.
- Manufacturing requires biologic processing and quality controls that are more difficult to replicate than a standard small-molecule tablet.
- The product has a global regulatory and commercial infrastructure already in place.
Revenue pressure is likely to come from tender pricing, local competitors, hospital formularies, and lower treatment intensity in settings that adopt less-invasive respiratory-support strategies.
When did CUROSURF lose exclusivity?
CUROSURF no longer has meaningful market exclusivity based on the original U.S. approval. The product was approved in 1999, and the 12-year reference-biologic exclusivity framework created by the Biologics Price Competition and Innovation Act was enacted in 2010. Any applicable reference-product exclusivity period for a product approved in 1999 would have expired long ago (FDA, 2020).
CUROSURF’s current commercial protection comes primarily from:
- Manufacturing complexity
- Product-specific know-how
- Regulatory history
- Clinical adoption
- Hospital contracts
- Supply reliability
- Brand recognition among neonatologists
These protections are practical rather than based on a live period of statutory exclusivity.
What is the CUROSURF patent expiration date?
A single current CUROSURF patent expiration date cannot be used to explain the product’s market position. The original product is an older biologic, and any foundational U.S. patent protection associated with the original formulation or production would not be expected to remain the primary barrier to competition.
The commercial moat is more likely to involve process controls, extraction and purification methods, raw-material sourcing, manufacturing scale, quality systems, and regulatory knowledge. Some such protections may be maintained as trade secrets rather than disclosed patent rights.
What is the Orange Book status of CUROSURF?
The Orange Book is primarily used for approved drug products submitted through new drug applications and abbreviated new drug applications. CUROSURF was approved as a biologic under a BLA, so its central U.S. regulatory reference point is the FDA biologics framework rather than an Orange Book patent listing (FDA, n.d.-a).
The practical consequences are significant:
- A conventional Orange Book Paragraph IV pathway is not the principal route for challenging CUROSURF.
- Patent certification litigation under the Hatch-Waxman framework is not the expected primary competitive mechanism.
- A potential follow-on product would generally require a biologics pathway or another applicable FDA route.
- The Purple Book and FDA biologics records are more relevant than the Orange Book for reference-product status and biosimilar analysis.
Which companies are challenging CUROSURF?
No clear U.S. Paragraph IV challenge is expected because CUROSURF is a BLA product rather than a conventional NDA product with Orange Book-listed patents. The relevant competitive set consists of alternative surfactant products and potential future follow-on biologics.
How does CUROSURF compare with Survanta and Infasurf?
| Product |
Active ingredient |
Source |
U.S. commercial position |
Competitive consideration |
| CUROSURF |
Poractant alfa |
Porcine lung |
Established Chiesi product |
High concentration, strong clinical familiarity |
| Survanta |
Beractant |
Bovine lung |
Established alternative |
Differentiated formulation and dosing profile |
| Infasurf |
Calfactant |
Calf lung |
Established alternative |
Competes through clinical use and contracting |
| Synthetic or next-generation products |
Varies |
Synthetic or recombinant |
Limited or emerging depending on product |
Could reduce dependence on animal-derived products |
CUROSURF has an advantage in installed clinical use and physician familiarity. Its competitors have similar market access through neonatal intensive-care formularies. The market is not protected by a single exclusive protocol.
What biosimilar risk exists for CUROSURF?
No FDA-approved biosimilar to CUROSURF is identified in the FDA’s publicly available Purple Book materials cited here (FDA, n.d.-b). That does not eliminate future follow-on risk.
A CUROSURF biosimilar or interchangeable product would face technical challenges:
- The active material is a complex mixture rather than a single recombinant protein.
- Biological activity depends on phospholipid composition and surfactant-associated proteins.
- Animal-source variability requires tight process controls.
- The product must meet sterility, purity, potency, and consistency requirements.
- Comparative clinical development may be required to establish sufficient similarity and support the intended indication.
For this reason, biosimilar entry is more difficult than generic entry for a simple chemical drug. The risk is best characterized as low in the near term but not permanently negligible.
What formulation and manufacturing protections affect CUROSURF?
CUROSURF’s strongest practical barriers are linked to formulation and manufacturing rather than an obvious active patent term.
The product must preserve pulmonary-surfactant activity during extraction, purification, concentration, sterilization, filling, storage, and administration. Key technical variables include:
- Phospholipid concentration
- Composition of surfactant-associated proteins
- Removal of contaminants
- Control of oxidation and degradation
- Sterility and endotoxin limits
- Batch consistency
- Cold-chain and inventory management
- Compatibility with neonatal administration equipment
Natural lung-derived products also depend on reliable biological raw materials and qualified processing facilities. A competitor can potentially reproduce the broad product concept while still facing substantial process-development and comparability work.
Manufacturing know-how can therefore delay competition even after formal patent protection has expired. It can also make supply disruptions commercially damaging because neonatal intensive-care units tend to prioritize continuity and validated products.
What FDA regulatory status applies to CUROSURF?
CUROSURF is an FDA-approved biologic for neonatal respiratory distress syndrome. Its label includes dosing, administration, contraindications, warnings, and handling instructions. The product is administered by trained clinicians in hospital settings and is not an outpatient retail medicine (FDA, 2023).
Regulatory factors supporting continued use include:
- Long post-approval clinical history
- Inclusion in neonatal treatment protocols
- Established hospital purchasing systems
- Familiarity among neonatologists and respiratory therapists
- Use in a narrow, high-acuity population
The principal regulatory risk is not withdrawal for loss of exclusivity. It is competition from products that demonstrate comparable clinical performance, easier administration, lower cost, or improved compatibility with noninvasive ventilation.
What patent litigation and settlement agreements affect CUROSURF?
No major active U.S. Paragraph IV litigation or settlement agreement is central to CUROSURF’s current market position based on the regulatory framework applicable to the product. Because CUROSURF is a BLA product, any future competition would more likely involve:
- A biosimilar application
- A separate biologic with comparative clinical data
- Patent litigation involving process, formulation, or manufacturing claims
- Regulatory exclusivity disputes
- Contracting or supply disputes
The absence of a conventional Paragraph IV case does not mean the product is free of intellectual-property risk. Process patents, formulation patents, trade secrets, and manufacturing evidence could become important if a follow-on developer reaches the market.
What generic launch scenarios exist for CUROSURF?
Three scenarios are commercially relevant.
Scenario 1: No near-term follow-on product
This is the base case. CUROSURF retains substantial share through clinical familiarity, supply reliability, and regulatory history. Price growth remains limited, but revenue is stable or grows with geographic expansion and neonatal-care volumes.
Scenario 2: Alternative branded surfactant gains share
Survanta, Infasurf, or another branded product wins hospital contracts through price, supply, or formulary positioning. The effect would be gradual because clinicians and hospitals often use established neonatal protocols.
Scenario 3: Follow-on biologic or new-generation surfactant launches
A lower-priced biosimilar or a synthetic/recombinant surfactant could create sharper price pressure. The entrant would need to demonstrate quality, clinical performance, manufacturing consistency, and reliable supply. Penetration would likely begin with tenders and selected hospital systems rather than immediate nationwide substitution.
How strong is the CUROSURF patent estate?
CUROSURF’s patent estate is less important than its product and manufacturing estate. The likely strength profile is:
| Protection category |
Current strategic strength |
| Original composition patents |
Low after decades on the market |
| Core regulatory exclusivity |
Expired |
| Orange Book-listed patents |
Not the principal framework |
| Manufacturing know-how |
Potentially strong |
| Raw-material sourcing |
Potentially meaningful |
| Clinical adoption |
Strong |
| Hospital contracting |
Moderate to strong |
| Biosimilar development barrier |
Moderate to high |
| Brand protection |
Strong in specialist neonatal care |
CUROSURF is therefore an example of a mature biologic whose commercial durability depends on execution, process complexity, and clinical entrenchment rather than a long remaining patent term.
What is the revenue exposure and investment outlook?
CUROSURF’s product-level revenue exposure cannot be calculated from Chiesi’s public group reporting. The investment conclusion must therefore rely on qualitative and company-level evidence.
The product is likely to remain a dependable specialty-care contributor because demand is recurring, treatment is concentrated in institutional settings, and technical substitution is difficult. Its ceiling is constrained by the size of the premature-infant population and by clinical efforts to reduce invasive ventilation and surfactant use.
The most important indicators to monitor are:
- Chiesi disclosures on respiratory-product performance
- U.S. and European neonatal-sur factant volumes
- Hospital tender outcomes
- Competitor supply reliability
- New biologic or synthetic surfactant filings
- FDA Purple Book additions
- Changes in neonatal respiratory-support guidelines
- Manufacturing capacity and product availability
- Pricing trends in public-sector and hospital contracts
Key Takeaways
- CUROSURF is poractant alfa, a mature porcine-lung-derived pulmonary surfactant approved by the FDA in 1999.
- Its core U.S. exclusivity period has expired.
- Orange Book Paragraph IV litigation is not the central competitive framework because CUROSURF is regulated under a BLA.
- No FDA-approved biosimilar is identified in the cited Purple Book materials.
- The principal barriers are manufacturing complexity, clinical familiarity, supply reliability, and hospital procurement relationships.
- Chiesi does not publicly disclose CUROSURF revenue separately.
- The product is more likely to provide durable specialty-care cash flow than rapid revenue growth.
- The main long-term threat is a credible lower-cost follow-on biologic or improved synthetic surfactant, not ordinary tablet-style generic substitution.
FAQs
Is CUROSURF still patent protected?
CUROSURF’s original market position is not dependent on an active foundational patent term. Manufacturing know-how, process controls, and undisclosed technical information may still protect the product commercially.
Is there a generic version of CUROSURF?
There is no conventional generic version identified through the standard small-molecule pathway. A competing product would likely require a biologic or other specialized regulatory route.
Who manufactures CUROSURF?
CUROSURF is developed and commercialized by Chiesi Farmaceutici, with Chiesi USA responsible for U.S. commercialization.
Can hospitals substitute another surfactant for CUROSURF?
Hospitals may use alternative FDA-approved surfactants, including Survanta or Infasurf, subject to institutional protocols, clinician judgment, availability, and payer or procurement terms.
Why is CUROSURF difficult to copy?
CUROSURF is a complex biologic mixture derived from porcine lung material. Reproducing its composition, biological activity, purity, sterility, manufacturing consistency, and clinical performance requires more than duplicating a chemical formula.
References
-
Chiesi Farmaceutici. (2024). Annual report and consolidated financial statements for the year ended December 31, 2023. Chiesi Farmaceutici S.p.A.
-
U.S. Food and Drug Administration. (2020). Purple Book: Lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations. https://www.fda.gov/drugs/biosimilars/purple-book
-
U.S. Food and Drug Administration. (2023). CUROSURF (poractant alfa) prescribing information. Chiesi USA, Inc.
-
U.S. Food and Drug Administration. (n.d.-a). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.-b). Purple Book database of licensed biological products. https://purplebooksearch.fda.gov/
-
World Health Organization. (2023). Born too soon: Decade of action on preterm birth. World Health Organization.
